


# DanDrit Biotech

**OTCQB:DDRT**

Developing the World's First  
Colorectal Cancer Vaccine



Investor Dagen - Copenhagen. March 2015

# Disclaimer

---

This presentation may contain forward-looking statements, including statements about our expectations of the progression of our pre-clinical and clinical pipeline including the timing for commencement and completion of clinical trials and with respect to cash burn guidance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. DanDrit cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: The risk that the drug development program of DanDrit will not proceed as planned for technical, scientific, or commercial reasons or due to patient enrollment issues or based on new information from non-clinical or clinical studies or from other sources; the success of competing products and technologies; technological uncertainty and product development risks; uncertainty of additional funding; DanDrit's history of incurring losses and the uncertainty of achieving profitability; DanDrit's stage of development as a biopharmaceutical company; government regulation; patent infringement claims against DanDrit's products, processes, and technologies; the ability to protect DanDrit's patents and proprietary rights; uncertainties relating to commercialization rights; and product liability exposure. Any forward-looking statements we make in this presentation speaks only as of the date of such statement and we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

You should read carefully the factors in the “Risk Factors” section of the prospectus contained in Amendment No. 2 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on May 16, 2014 for our proposed public offering.

# Developing the World's First Colorectal Cancer Vaccine

## **MCV: first-in-class targeted immunotherapy**

- in the adjuvant setting to prevent recurrence of metastatic colorectal cancer


## **VIVA Phase III trial**

- starts enrolling



## **Operationally ready for commercialization**

- agreement with myTomorrows provides early access to MCV to terminally ill patients


# Colorectal Cancer Vaccine: Significant Market Opportunity



# Major Unmet Medical Need



# Major Unmet Medical Need




Leonard B. Saltz. *Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study.* 2008 American Society of Clinical Oncology

# VIVA

**MelCancerVac **V**accine in  
patients with stage **IV**  
colorectal cancer with no  
evidence of disease after  
standard of care:  
a randomized Phase **III**  
**A**djuvant study**

# VIVA : Phase III Clinical Trial Stage IV CRC

Stage IV colorectal cancer patients after resection and chemotherapy.  
No Evidence of Disease.




**Randomized Seamless Adaptive Phase II/III  
Multicenter Italy with GISCAD  
PI: Pr. A. Sobrero  
IDSMC: Pr. Axel Grothey (Mayo Clinic)**



# 2<sup>nd</sup> Generation of Cancer Vaccines

Patient friendly: intradermal injections  
Frozen product  
Compatible with standard of care  
Pricing in line with new cancer drugs



# Operationally Ready for Commercialization

## Agreement with MyTomorrows

- worldwide online platform providing access to non-registered medicines for patients with life threatening or debilitating diseases
- turnkey solution: permits recruitment, logistics, pharmacovigilance

## Change the traditional value creation curve

- generate revenues in 2015
- real life data
- ongoing pre-marketing during registration and reimbursement period
- instant successful market launch, without traditional lag phase
- access to new emerging markets

# Operationally Ready for Commercialization



- MyTomorrows, The Netherlands: PNUP
- Cellin Technologies, Estonia: GMP vaccine manufacturing EU
- Riyadh Pharma, Saudi Arabia: GMP vaccine manufacturing MENA



# Strategy

**Adjuvant therapy after standard of care to prevent colon cancer recurrence**

- VIVA Phase III trial with GISCAD

**Commercial readiness through profitable patient name use program (PNUP)**

- first Europe
- followed by MENA and US

**Possible exit through trade sale within 3 years**


- short list of potential buyers

# Financial Overview

Consolidated, Unaudited, January 31, 2015, (000's except Shares Outstanding)


Cash, cash equivalent	\$ 7,775
Debt	\$ 0
Projected quarterly burn for 2015	\$ 232
Shares outstanding	9,533,290
Market cap (February 2015)	\$ 57,200

Market Cap \$57.2






# Developing the World's First Colorectal Cancer Vaccine


Game-changing investment  
in a growing market  
unaffected by economic conditions



**Thank You**  
[www.dandrit.com](http://www.dandrit.com)



# MelCancerVac® (MCV): Harnessing the Power of the Immune System



Fast generation of Dendritic cells  
Kvistborg P. et al, *Cellular Immunology*, 2009



# 2<sup>nd</sup> Generation of Cancer Vaccines

